Terns Pharma FY2023 net loss $90.2M; cash $263.4M; key trial data expected H2 2024

Terns Pharmaceuticals, Inc.

Net loss of $21.0M in Q4 2023 and $90.2M for full year 2023, vs $15.8M and $60.3M in prior year.
Cash, equivalents and securities $263.4M at Dec 31, 2023; funding expected into 2026.
CEO Amy Burroughs appointed in Feb 2024; FDA orphan drug designation for TERN-701 (CML) in March 2024.
Phase 1 TERN-701 CARDINAL interim data and TERN-601 (GLP-1) 28-day weight loss data both expected H2 2024.
R&D spend rose to $63.5M in FY2023 (from $39.6M) as clinical programs advanced.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Terns Pharmaceuticals, Inc. reported financial results for fourth quarter and full year ended December 31, 2023.

Period: fourth quarter and full year ended December 31, 2023
Result: reported results

Exact text from the filing

On March 14, 2024, Terns Pharmaceuticals, Inc. issued a press release announcing its financial results for the year ended December 31, 2023.

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

Terns Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-031468

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.